Literature DB >> 17430676

Reassessment of statins to retard the progression of aortic stenosis.

Nalini M Rajamannan1.   

Abstract

Aortic valve stenosis is the most common indication for surgical valve replacement in the United States and Europe. For years, this valve lesion was thought to be a passive degenerative disease. In the past decade there have been a number of studies indicating that the risk factors for valvular heart disease are the same as those for vascular atherosclerosis. This correlation with atherosclerosis and valvular heart disease indicates that medical therapy may have a role in slowing the progression of this disease process. Currently, the retrospective studies indicate that medical therapy slows the progression of this disease. The prospective data are currently conflicting in terms of the final outcomes for treating the disease process with medical therapy. This review outlines the growing number of clinical studies implicating the potential for medical therapy in this patient population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430676     DOI: 10.1007/bf02938335

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  39 in total

1.  Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve.

Authors:  K L Chan; M Ghani; K Woodend; I G Burwash
Journal:  Am J Cardiol       Date:  2001-09-15       Impact factor: 2.778

2.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

3.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

4.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

5.  Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; J Thyberg; J Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

6.  Human aortic valve calcification is associated with an osteoblast phenotype.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

7.  C-reactive protein is increased in patients with degenerative aortic valvular stenosis.

Authors:  A Galante; A Pietroiusti; M Vellini; P Piccolo; G Possati; M De Bonis; R L Grillo; C Fontana; C Favalli
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

8.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

Authors:  K D O'Brien; D D Reichenbach; S M Marcovina; J Kuusisto; C E Alpers; C M Otto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-04       Impact factor: 8.311

9.  Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.

Authors:  Kevin D O'Brien; Xue-Qiao Zhao; David M Shavelle; Michael T Caulfield; Rebecca A Letterer; Samir R Kapadia; Jeffrey L Probstfield; Catherine M Otto
Journal:  J Investig Med       Date:  2004-04       Impact factor: 2.895

10.  The relative importance of the major risk factors in atherosclerotic and other diseases.

Authors:  H M Whyte
Journal:  Aust N Z J Med       Date:  1976-10
View more
  2 in total

Review 1.  The regulation of valvular and vascular sclerosis by osteogenic morphogens.

Authors:  Kristina I Boström; Nalini M Rajamannan; Dwight A Towler
Journal:  Circ Res       Date:  2011-08-19       Impact factor: 17.367

2.  Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans.

Authors:  Jordan D Miller; Yi Chu; Robert M Brooks; Wayne E Richenbacher; Ricardo Peña-Silva; Donald D Heistad
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.